Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?

Circ Res. 2009 Jan 2;104(1):1-3. doi: 10.1161/CIRCRESAHA.108.191122.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Angiotensin II / physiology
  • Angiotensin II / toxicity
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Animals
  • Cardiomegaly / chemically induced
  • Cardiomegaly / drug therapy
  • Cardiomegaly / physiopathology*
  • Cardiomegaly / prevention & control
  • Cytokines / metabolism
  • Drug Delivery Systems
  • ErbB Receptors / physiology
  • Fibroblasts / drug effects
  • Fibroblasts / physiology*
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Heart Failure / metabolism
  • Heart Failure / pathology
  • Heparin-binding EGF-like Growth Factor
  • Humans
  • Intercellular Signaling Peptides and Proteins / physiology
  • Isoproterenol / toxicity
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases / physiology
  • Mice
  • Mice, Transgenic
  • Myocardium / metabolism
  • Myocardium / pathology*
  • Rats
  • Receptor, Angiotensin, Type 1 / physiology
  • Receptor, Serotonin, 5-HT2B / physiology*
  • Serotonin 5-HT2 Receptor Antagonists
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / therapeutic use
  • Signal Transduction / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Cytokines
  • HBEGF protein, human
  • Hbegf protein, mouse
  • Hbegf protein, rat
  • Heparin-binding EGF-like Growth Factor
  • Intercellular Signaling Peptides and Proteins
  • Matrix Metalloproteinase Inhibitors
  • Receptor, Angiotensin, Type 1
  • Receptor, Serotonin, 5-HT2B
  • Serotonin 5-HT2 Receptor Antagonists
  • Serotonin Antagonists
  • Angiotensin II
  • ErbB Receptors
  • Matrix Metalloproteinases
  • Isoproterenol